Apolipoprotein A-I mimetic peptide inhibits atherosclerosis by altering plasma metabolites in hypercholesterolemia

American Journal of Physiology - Endocrinology and Metabolism

Volumn 303, Issue 6, 2012, Pages

  Ou, Zhi Jun ^a   Li, Li ^b,c   Liao, Xiao Long ^a   Wang, Yi Ming ^b,c   Hu, Xiao Xia ^a   Zhang, Qing Li ^c,d   Wang, Zhi Ping ^a   Yu, Huan ^b,c   Zhang, Xi ^a   Hu, Ping ^d   Xu, Ying Qi ^a   Liang, Qiong Lin ^b,c   Ou, Jing Song ^a   Luo, Guoan ^b,c  

^a SUN YAT SEN UNIVERSITY   (China)

^b GUANGZHOU UNIVERSITY OF CHINESE MEDICINE   (China)

^c TSINGHUA UNIVERSITY   (China)

^d EAST CHINA UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

Metabonomics; Potential biomarker

Indexed keywords

APOLIPOPROTEIN A1; DIACYLGLYCEROL; LYSOPHOSPHATIDYLCHOLINE; PHOSPHATIDYLCHOLINE; PHOSPHATIDYLETHANOLAMINE; PROTEIN D 4F; SPHINGOMYELIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ATHEROSCLEROSIS; CONTROLLED STUDY; FEMALE; HYPERCHOLESTEROLEMIA; METABOLISM; METABOLOMICS; MOUSE; MULTIVARIATE ANALYSIS; NEGATIVE ION ELECTROSPRAY; NONHUMAN; PARTIAL LEAST SQUARES REGRESSION; POSITIVE ION ELECTROSPRAY; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; TANDEM MASS SPECTROMETRY; TIME OF FLIGHT MASS SPECTROMETRY; ULTRA PERFORMANCE LIQUID CHROMATOGRAPHY;

ANIMALS; AORTA; APOLIPOPROTEIN A-I; ATHEROSCLEROSIS; BIOLOGICAL MARKERS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DIET, ATHEROGENIC; FEMALE; HYPERCHOLESTEROLEMIA; HYPOLIPIDEMIC AGENTS; INJECTIONS, INTRAPERITONEAL; LIPIDS; LYSOPHOSPHATIDYLCHOLINES; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; PLAQUE, ATHEROSCLEROTIC; RECEPTORS, LDL; SPECTROMETRY, MASS, ELECTROSPRAY IONIZATION; VASODILATOR AGENTS;

EID: 84866385899     PISSN: 01931849     EISSN: 15221555     Source Type: Journal    
DOI: 10.1152/ajpendo.00136.2012     Document Type: Article

References (52)

1. Aiyar N, Disa J, Ao Z, Ju H, Nerurkar S, Willette RN, Macphee CH, Johns DG, Douglas SA. Lysophosphatidylcholine induces inflammatory activation of human coronary artery smooth muscle cells. Mol Cell Biochem 295: 113-120, 2007.
2. Anantharamaiah GM, Mishra VK, Garber DW, Datta G, Handattu SP, Palgunachari MN, Chaddha M, Navab M, Reddy ST, Segrest JP, Fogelman AM. Structural requirements for antioxidative and anti-inflammatory properties of apolipoprotein A-I mimetic peptides. J Lipid Res 48: 1915-1923, 2007.
3. Bernini P, Bertini I, Luchinat C, Tenori L, Tognaccini A. The cardiovascular risk of healthy individuals studied by NMR metabonomics of plasma samples. J Proteome Res 10: 4983-4992, 2011.
4. Brindle JT, Antti H, Holmes E, Tranter G, Nicholson JK, Bethell HW, Clarke S, Schofield PM, McKilligin E, Mosedale DE, Grainger DJ. Rapid and noninvasive diagnosis of the presence and severity of coronary heart disease using 1H-NMR-based metabonomics. Nat Med 8: 1439-1444, 2002.
5. Chen L, Liang B, Froese DE, Liu S, Wong JT, Tran K, Hatch GM, Mymin D, Kroeger EA, Man RY, Choy PC. Oxidative modification of low density lipoprotein in normal and hyperlipidemic patients: effect of lysophosphatidylcholine composition on vascular relaxation. J Lipid Res 38: 546-553, 1997.
6. Clayton TA, Baker D, Lindon JC, Everett JR, Nicholson JK. Pharmacometabonomic identification of a significant host-microbiome metabolic interaction affecting human drug metabolism. Proc Natl Acad Sci USA 106: 14728-14733, 2009.
7. Datta G, Chaddha M, Hama S, Navab M, Fogelman AM, Garber DW, Mishra VK, Epand RM, Epand RF, Lund-Katz S, Phillips MC, Segrest JP, Anantharamaiah GM. Effects of increasing hydrophobicity on the physical-chemical and biological properties of a class A amphipathic helical peptide. J Lipid Res 42: 1096-1104, 2001.
8. Gross RW, Han X. Shotgun lipidomics of neutral lipids as an enabling technology for elucidation of lipid-related diseases. Am J Physiol Endocrinol Metab 297: E297-E303, 2009.
9. Han KH, Hong KH, Ko J, Rhee KS, Hong MK, Kim JJ, Kim YH, Park SJ. Lysophosphatidylcholine up-regulates CXCR4 chemokine receptor expression in human CD4 T cells. J Leukoc Biol 76: 195-202, 2004.
10. Inoue N, Takeshita S, Gao D, Ishida T, Kawashima S, Akita H, Tawa R, Sakurai H, Yokoyama M. Lysophosphatidylcholine increases the secretion of matrix metalloproteinase 2 through the activation of NADH/ NADPH oxidase in cultured aortic endothelial cells. Atherosclerosis 155: 45-52, 2001.
11. Kim HJ, Kim JH, Noh S, Hur HJ, Sung MJ, Hwang JT, Park JH, Yang HJ, Kim MS, Kwon DY, Yoon SH. Metabolomic analysis of livers and serum from high-fat diet induced obese mice. J Proteome Res 10: 722-731, 2011.
12. Kugiyama K, Kerns SA, Morrisett JD, Roberts R, Henry PD. Impairment of endothelium-dependent arterial relaxation by lysolecithin in modified low-density lipoproteins. Nature 344: 160-162, 1990.
13. Liang X, Chen X, Liang Q, Zhang H, Hu P, Wang Y, Luo G. Metabonomic study of Chinese medicine Shuanglong formula as an effective treatment for myocardial infarction in rats. J Proteome Res 10: 790-799, 2011.
14. Lin H, Zhang J, Gao P. Silent myocardial ischemia is associated with altered plasma phospholipids. J Clin Lab Anal 23: 45-50, 2009.
15. Lindon JC, Nicholson JK. Analytical technologies for metabonomics and metabolomics, and multi-omic information recovery TrAC-Trend. Anal Chem 27: 194-204, 2008.
16. Liu S, Lu X, Choy S, Dembinski T, Hatch G, Mymin D, Shen X, Angel A, Choy P, Man R. Alteration of lysophosphatidylcholine content in low density lipoprotein after oxidative modification: relationship to endothelium dependent relaxation. Cardiovasc Res 28: 1476-1481, 1994.
17. Lu X, Zhao X, Bai C, Zhao C, Lu G, Xu G. LC-MS-based metabonomics analysis. J Chromatogr B Analyt Technol Biomed Life Sci 866: 64-76, 2008.
18. Lv H, Liu L, Zhang Y, Song T, Lu J, Chen X. Ingenuity pathways analysis of urine metabonomics phenotypes toxicity of gentamicin in multiple organs. Mol Biosyst 6: 2056-2067, 2010.
19. Lv Y, Liu X, Yan S, Liang X, Yang Y, Dai W, Zhang W. Metabolomic study of myocardial ischemia and intervention effects of Compound Danshen Tablets in rats using ultra-performance liquid chromatography/ quadrupole time-of-flight mass spectrometry. J Pharm Biomed Anal 52: 129-135, 2010.
20. Magret V, Elkhalil L, Nazih-Sanderson F, Martin F, Bourre JM, Fruchart JC, Delbart C. Entry of polyunsaturated fatty acids into the brain: evidence that high-density lipoprotein-induced methylation of phosphatidylethanolamine and phospholipase A2 are involved. Biochem J 316: 805-811, 1996.
21. Mally A, Amberg A, Hard GC, Dekant W. Are 4-hydroxy-2(E)-nonenal derived mercapturic acids and (1)H NMR metabonomics potential biomarkers of chemically induced oxidative stress in the kidney? Toxicology 230: 244-255, 2007.
22. Matsumoto T, Kobayashi T, Kamata K. Role of lysophosphatidylcholine (LPC) in atherosclerosis. Curr Med Chem 14: 3209-3220, 2007.
23. Morgantini C, Imaizumi S, Grijalva V, Navab M, Fogelman AM, Reddy ST. Apolipoprotein A-I mimetic peptides prevent atherosclerosis development and reduce plaque inflammation in a murine model of diabetes. Diabetes 59: 3223-3228, 2010.
24. Navab M, Anantharamaiah GM, Hama S, Garber DW, Chaddha M, Hough G, Lallone R, Fogelman AM. Oral administration of an Apo A-I mimetic Peptide synthesized from D-amino acids dramatically reduces atherosclerosis in mice independent of plasma cholesterol. Circulation 105: 290-292, 2002.
25. Navab M, Anantharamaiah GM, Hama S, Hough G, Reddy ST, Frank JS, Garber DW, Handattu S, Fogelman AM. D-4F and statins synergize to render HDL antiinflammatory in mice and monkeys and cause lesion regression in old apolipoprotein E-null mice. Arterioscler Thromb Vasc Biol 25: 1426-1432, 2005.
26. Navab M, Anantharamaiah GM, Reddy ST, Hama S, Hough G, Grijalva VR, Yu N, Ansell BJ, Datta G, Garber DW, Fogelman AM. Apolipoprotein A-I mimetic peptides. Arterioscler Thromb Vasc Biol 25: 1325-1331, 2005.
27. Navab M, Anantharamaiah GM, Reddy ST, Van Lenten BJ, Wagner AC, Hama S, Hough G, Bachini E, Garber DW, Mishra VK, Palgunachari MN, Fogelman AM. An oral apoJ peptide renders HDL antiinflammatory in mice and monkeys and dramatically reduces atherosclerosis in apolipoprotein E-null mice. Arterioscler Thromb Vasc Biol 25: 1932-1937, 2005.
28. Navab M, Reddy ST, Van Lenten BJ, Anantharamaiah GM, Fogelman AM. The role of dysfunctional HDL in atherosclerosis. J Lipid Res 50, Suppl: S145-S149, 2009.
29. Nicholson JK, Connelly J, Lindon JC, Holmes E. Metabonomics: a platform for studying drug toxicity and gene function. Nat Rev Drug Discov 1: 153-161, 2002.
30. Oresic M, Vidal-Puig A, Hanninen V. Metabolomic approaches to phenotype characterization and applications to complex diseases. Expert Rev Mol Diagn 6: 575-585, 2006.
31. Ota N, Soga S, Hase T, Tokimitsu I, Murase T. Dietary diacylglycerol induces the regression of atherosclerosis in rabbits. J Nutr 137: 1194-1199, 2007.
32. Ou J, Ou Z, Jones DW, Holzhauer S, Hatoum OA, Ackerman AW, Weihrauch DW, Gutterman DD, Guice K, Oldham KT, Hillery CA, Pritchard KA Jr. L-4F, an apolipoprotein A-1 mimetic, dramatically improves vasodilation in hypercholesterolemia and sickle cell disease. Circulation 107: 2337-2341, 2003.
33. Ou J, Wang J, Xu H, Ou Z, Sorci-Thomas MG, Jones DW, Signorino P, Densmore JC, Kaul S, Oldham KT, Pritchard KA Jr. Effects of D-4F on vasodilation and vessel wall thickness in hypercholesterolemic LDL receptor-null and LDL receptor/apolipoprotein A-I double-knockout mice on Western diet. Circ Res 97: 1190-1197, 2005.
34. Ou Z, Ou J, Ackerman AW, Oldham KT, Pritchard KA Jr. L-4F, an apolipoprotein A-1 mimetic, restores nitric oxide and superoxide anion balance in low-density lipoprotein-treated endothelial cells. Circulation 107: 1520-1524, 2003.
35. Pang LQ, Liang QL, Wang YM, Ping L, Luo GA. Simultaneous determination and quantification of seven major phospholipid classes in human blood using normal-phase liquid chromatography coupled with electrospray mass spectrometry and the application in diabetes nephropathy. J Chromatogr B Analyt Technol Biomed Life Sci 869: 118-125, 2008.
36. Park TS, Panek RL, Rekhter MD, Mueller SB, Rosebury WS, Robertson A, Hanselman JC, Kindt E, Homan R, Karathanasis SK. Modulation of lipoprotein metabolism by inhibition of sphingomyelin synthesis in ApoE knockout mice. Atherosclerosis 189: 264-272, 2006.
37. Plane F, Bruckdorfer KR, Kerr P, Steuer A, Jacobs M. Oxidative modification of low-density lipoproteins and the inhibition of relaxations mediated by endothelium-derived nitric oxide in rabbit aorta. Br J Pharmacol 105: 216-222, 1992.
38. Pruzanski W, Stefanski E, de Beer FC, de Beer MC, Ravandi A, Kuksis A. Comparative analysis of lipid composition of normal and acute-phase high density lipoproteins. J Lipid Res 41: 1035-1047, 2000.
39. Quinn MT, Parthasarathy S, Steinberg D. Lysophosphatidylcholine: a chemotactic factor for human monocytes and its potential role in atherogenesis. Proc Natl Acad Sci USA 85: 2805-2809, 1988.
40. Roussel R, Mentré F, Bouchemal N, Hadjadj S, Lièvre M, Chatellier G, Menard J, Panhard X, Le Hénanff A, Marre M, Le Moyec L; DIABHYCAR Study Group. NMR-based prediction of cardiovascular risk in diabetes. Nat Med 13: 399-400, 2007.
41. Sabatine MS, Liu E, Morrow DA, Heller E, McCarroll R, Wiegand R, Berriz GF, Roth FP, Gerszten RE. Metabolomic identification of novel biomarkers of myocardial ischemia. Circulation 112: 3868-3875, 2005.
42. Su Y, Block ER. Role of calpain in hypoxic inhibition of nitric oxide synthase activity in pulmonary endothelial cells. Am J Physiol Lung Cell Mol Physiol 278: L1204-L1212, 2000.
43. Sun C, Teng Y, Li G, Yoshioka S, Yokota J, Miyamura M, Fang H, Zhang Y. Metabonomics study of the protective effects of Lonicera japonica extract on acute liver injury in dimethylnitrosamine treated rats. J Pharm Biomed Anal 53: 98-102, 2010.
44. Sun J, Schnackenberg LK, Holland RD, Schmitt TC, Cantor GH, Dragan YP, Beger RD. Metabonomics evaluation of urine from rats given acute and chronic doses of acetaminophen using NMR and UPLC/ MS. J Chromatogr B Analyt Technol Biomed Life Sci 871: 328-340, 2008.
45. van Doorn M, Vogels J, Tas A, van Hoogdalem EJ, Burggraaf J, Cohen A, van der Greef J. Evaluation of metabolite profiles as biomarkers for the pharmacological effects of thiazolidinediones in Type 2 diabetes mellitus patients and healthy volunteers. Br J Clin Pharmacol 63: 562-574, 2007.
46. Van Lenten BJ, Wagner AC, Anantharamaiah GM, Garber DW, Fishbein MC, Adhikary L, Nayak DP, Hama S, Navab M, Fogelman AM. Influenza infection promotes macrophage traffic into arteries of mice that is prevented by D-4F, an apolipoprotein A-I mimetic peptide. Circulation 106: 1127-1132, 2002.
47. Zhang F, Jia Z, Gao P, Kong H, Li X, Chen J, Yang Q, Yin P, Wang J, Lu X, Li F, Wu Y, Xu G. Metabonomics study of atherosclerosis rats by ultra fast liquid chromatography coupled with ion trap-time of flight mass spectrometry. Talanta 79: 836-844, 2009.
48. Zhang HY, Chen X, Hu P, Liang QL, Liang XP, Wang YM, Luo GA. Metabolomic profiling of rat serum associated with isoproterenol-induced myocardial infarction using ultra-performance liquid chromatography/ time-of-flight mass spectrometry and multivariate analysis. Talanta 79: 254-259, 2009.
49. Zhang J, Yan L, Chen W, Lin L, Song X, Yan X, Hang W, Huang B. Metabonomics research of diabetic nephropathy and type 2 diabetes mellitus based on UPLC-oaTOF-MS system. Anal Chim Acta 650: 16-22, 2009.
50. Zhang Z, Qiu Y, Hua Y, Wang Y, Chen T, Zhao A, Chi Y, Pan L, Hu S, Li J, Yang C, Li G, Sun W, Cai Z, Jia W. Serum and urinary metabonomic study of human osteosarcoma. J Proteome Res 9: 4861-4868, 2010.
51. Zhao X, Peter A, Fritsche J, Elcnerova M, Fritsche A, Häring HU, Schleicher ED, Xu G, Lehmann R. Changes of the plasma metabolome during an oral glucose tolerance test: is there more than glucose to look at? Am J Physiol Endocrinol Metab 296: E384-E393, 2009.
52. Zheng X, Shen J, Liu Q, Wang S, Cheng Y, Qu H. Plasma fatty acids metabolic profiling analysis of coronary heart disease based on GC-MS and pattern recognition. J Pharm Biomed Anal 49: 481-486, 2009.